NCT00483509View on ClinicalTrials.gov

Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 14, 2007

Primary Completion Date

September 22, 2010

Study Completion Date

May 17, 2011

Conditions
Small Cell Lung Cancer
Interventions
DRUG

NGR-hTNF

iv q3W 0.8 mcg/sqm NGR-hTNF

DRUG

Doxorubicin

iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion

Trial Locations (5)

10043

Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano

16132

Azienda Ospedaliera Universitaria San Martino, Genoa

Istituto Nazionale per la Ricerca sul Cancro, Genoa

20089

Istituto Clinico Humanitas, Rozzano

20132

Fondazione San Raffaele del Monte Tabor, Milan

Sponsors
All Listed Sponsors
lead

AGC Biologics S.p.A.

INDUSTRY